Levcromakalim

DB21154InvestigationalSmall molecule

Levcromakalim is a small molecule drug. The usage of the INN stem '-kalim' in the name indicates that Levcromakalim is a potassium channel activator, antihypertensive. Levcromakalim is under investigation in... Levcromakalim is under investigation in clinical trial NCT04853797 (Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)).

Mechanism: Pharmacologically active on ATP-binding cassette sub-family C member 9 and ATP-sensitive potassium channel
Curator reviewed
Formula / weight: C₁₆H₁₈N₂O₃ · 286.331 g/mol (avg)
Code names: BRL-38227

Resolves to

Compound

UNIIRW7PN4BLDJCAS94535-50-9ChEMBLCHEMBL100ChEBI6436PubChem93504KEGGC11697

Structure

InChIKeyTVZCRIROJQEVOT-CABCVRRESA-NSMILESCC1(C)OC2=C(C=C(C=C2)C#N)[C@H]([C@@H]1O)N1CCCC1=O

Targets

O60706ABCC9

Transporters

P13569CFTR

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Levcromakalim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In